Skip to main content
S&P 5007,591.70-0.58%DOW52,064.10-0.60%NASDAQ26,081.72-0.65%BTC$76,759.00-1.92%ETH$2,449.71-0.78%GOLD$4,364.00-0.98%OIL$103.08+0.59%
Smart Investors Daily
OL

NASDAQ · OLMA

Olema Pharmaceuticals, Inc.

Healthcare · Biotechnology

$10.36

Up+$0.33 (+3.19%)

Updated Sep 11, 2026, 12:33 AM

SID Score

4.5/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
2.17B
P/E ratio
-18.05
Dividend yield
0.00%
52-week range
$6.65 – $36.26
Volume
863.84K
Avg. volume
3.41M

Price performance

OLMA price history

1M range · 19 trading sessions · Daily adjusted prices

OLMA closed at $10.36 after 19 trading sessions, down 1.43% for the selected period.

Last close
$10.36
Period change
-1.43%
Period low
$10.27
Period high
$11.31
Daily close
View OHLC price history
OLMA OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 9, 2026$11.13$11.18$10.35$10.36863.84K
Sep 8, 2026$10.61$11.055$10.46$10.985736.72K
Sep 4, 2026$10.61$10.85$10.57$10.75505.27K
Sep 3, 2026$10.71$10.98$10.58$10.73773.32K
Sep 2, 2026$10.58$11.02$10.475$10.83866.43K
Sep 1, 2026$10.36$10.63$10.28$10.56766.11K
Aug 31, 2026$10.20$10.53$10.0859$10.43937.03K
Aug 28, 2026$10.69$10.77$10.19$10.27740.85K
Aug 27, 2026$10.70$10.92$10.62$10.79383.35K
Aug 26, 2026$10.78$10.965$10.575$10.85472.34K
Aug 25, 2026$10.60$11.02$10.595$10.91799.92K
Aug 24, 2026$10.58$10.62$10.29$10.43727.33K
Aug 21, 2026$10.90$11.24$10.65$10.69748.7K
Aug 20, 2026$11.10$11.12$10.67$10.901.04M
Aug 19, 2026$10.90$11.36$10.765$11.311.76M
Aug 18, 2026$10.69$10.88$10.51$10.65960.52K
Aug 17, 2026$10.61$10.95$10.51$10.77889.85K
Aug 14, 2026$10.44$10.75$10.29$10.631.16M
Aug 13, 2026$10.36$10.6172$10.2665$10.511.15M

Latest OLMA news

The latest Smart Investors Daily articles mentioning OLMA.

Stock researchCompany · Overview

OLMA research

Overview

Company profile and research snapshot.

Company profile

Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$42.80
Implied upside
—
Analysts
—
OLMA recent ratings
DateFirmRatingTarget
Aug 13, 2026JP MorganOverweight—
Aug 11, 2026CitigroupBuy—
Aug 11, 2026HC Wainwright & Co.Buy—
May 13, 2026GuggenheimBuy—
Mar 27, 2026Wolfe ResearchPeer Perform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 2, 2026

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN FRANCISCO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that, in connection with the appointment of Jason V. O’Byrne as Chief Financial Officer effective August 11, 2026, the Company granted Mr. O’Byrne an employment inducement award consisting of stock options

Yahoo · Aug 31, 2026

Olema Oncology to Participate in Upcoming Investor Conferences

SAN FRANCISCO, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company will participate in the following upcoming investor conferences: Citi 2026 Biopharma Back to School Conference Date and Time: September 10, 2026 at 1 p.m. ET Format: Fireside ChatLocation:

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By